MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
Merck & Co. Book Value 2011-2026 | MRK
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Merck & Co.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 137 B | 117 B | 107 B | 109 B | 106 B | 91.6 B | 26 B | 26.9 B | 34.6 B | 40.3 B | 44.8 B | 48.8 B | 52.3 B | 55.5 B | 56.9 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 137 B | 26 B | 70.2 B |
Quarterly Book Value Merck & Co.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 130 B | 118 B | 115 B | 118 B | 113 B | 106 B | 107 B | 104 B | 108 B | 109 B | 107 B | - | 107 B | 106 B | 93.5 B | 90.7 B | 90.8 B | 91.6 B | 91.6 B | 91.6 B | 91.6 B | 84.4 B | 84.4 B | 84.4 B | 84.4 B | 82.6 B | 82.6 B | 82.6 B | 82.6 B | 87.9 B | 87.9 B | 87.9 B | 87.9 B | 95.4 B | 95.4 B | 95.4 B | 95.4 B | 102 B | 102 B | 102 B | 102 B | 98.2 B | 98.3 B | 98.3 B | 98.3 B | 106 B | 106 B | 106 B | 106 B | 106 B | 106 B | 106 B | 106 B | 105 B | 105 B | 105 B | 105 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 130 B | 82.6 B | 99.2 B |
Book Value of other stocks in the Biotechnology industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
49 M | - | 2.43 % | $ 254 M |  Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
789 M | $ 21.87 | 2.15 % | $ 1.02 B |  USA |
 |
I-Mab
IMAB
|
5.63 B | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | USA |
 |
Midatech Pharma plc
MTP
|
11.4 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
253 M | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
13.8 M | $ 0.94 | 5.23 % | $ 6.91 M | China |
 |
Biophytis SA
BPTS
|
34.9 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
282 M | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
733 M | $ 22.67 | 3.23 % | $ 3.76 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.33 B | - | -1.52 % | $ 24.7 M | USA |
 |
Esperion Therapeutics
ESPR
|
-302 M | $ 2.02 | 5.5 % | $ 420 M | USA |
 |
Advaxis
ADXS
|
16.6 M | - | -9.65 % | $ 45.9 M | USA |
 |
AIkido Pharma
AIKI
|
69.4 M | - | 1.93 % | $ 17.4 M | USA |
 |
Galectin Therapeutics
GALT
|
-126 M | $ 2.45 | 5.15 % | $ 157 M | USA |
 |
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
169 M | - | - | $ 28.6 M | USA |
 |
Heron Therapeutics
HRTX
|
14.3 M | $ 1.2 | 0.42 % | $ 200 M | USA |
 |
AlloVir
ALVR
|
78.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
3.36 M | - | -11.43 % | $ 502 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
10.6 M | - | - | - |  Russia |
 |
Applied Molecular Transport
AMTI
|
60.8 M | - | - | $ 10.1 M | USA |
 |
ImmuCell Corporation
ICCC
|
27.1 M | $ 8.24 | -1.38 % | $ 74.4 M | USA |
 |
Aeterna Zentaris
AEZS
|
3.84 M | - | 5.93 % | $ 314 M |  Canada |
 |
InflaRx N.V.
IFRX
|
41.6 M | $ 1.52 | 2.36 % | $ 152 M | Germany |
 |
Brainstorm Cell Therapeutics
BCLI
|
-9.98 M | - | -2.5 % | $ 5.88 M | USA |
 |
Applied Therapeutics
APLT
|
-17.1 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
38.3 M | - | -39.0 % | $ 4.57 M | USA |
 |
AgeX Therapeutics
AGE
|
-37 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
10.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-24.2 M | - | 17.91 % | $ 11.1 M | USA |
 |
BioNTech SE
BNTX
|
19.2 B | $ 103.09 | -2.25 % | $ 27.2 B | Germany |
 |
Avenue Therapeutics
ATXI
|
1.83 M | - | -52.27 % | $ 4.45 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | USA |
 |
Innate Pharma S.A.
IPHA
|
267 M | $ 1.36 | -1.45 % | $ 235 M | France |
 |
Aquestive Therapeutics
AQST
|
-33.7 M | $ 4.17 | 2.21 % | $ 446 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
189 M | $ 23.73 | 2.02 % | $ 3.02 B | USA |
 |
Inventiva S.A.
IVA
|
-107 M | $ 5.18 | 0.49 % | $ 138 M | France |
 |
Jaguar Health
JAGX
|
-18.7 M | $ 0.35 | -9.42 % | $ 816 K | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.77 M | - | - | $ 7.46 M |  Israel |
 |
Autolus Therapeutics plc
AUTL
|
178 M | $ 1.45 | 0.35 % | $ 386 M | Britain |
 |
Aptose Biosciences
APTO
|
-27.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
KalVista Pharmaceuticals
KALV
|
-2.71 M | $ 20.06 | 2.18 % | $ 1.08 B | Britain |
 |
AstraZeneca PLC
AZN
|
48.7 B | - | - | $ 96.9 B | Britain |
 |
AVROBIO
AVRO
|
94.7 M | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
20.3 M | $ 3.03 | 4.12 % | $ 4.99 M | Israel |
 |
BioDelivery Sciences International
BDSI
|
188 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
4.36 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
830 M | $ 233.96 | 1.16 % | $ 4.28 B | USA |